These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 12464661)

  • 21. Molecular diagnosis of cystic fibrosis.
    Shrimpton AE
    Expert Rev Mol Diagn; 2002 May; 2(3):240-56. PubMed ID: 12050863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel mutation (A141D) in exon 4 of the CFTR gene identified in an Algerian patient.
    Gouya L; Pascaud O; Munck A; Elion J; Denamur E
    Hum Mutat; 1997; 10(1):86-7. PubMed ID: 9222768
    [No Abstract]   [Full Text] [Related]  

  • 23. Sweat chloride concentration in cystic fibrosis patients with cystic fibrosis trans-membrane conductance regulator 11234V mutation.
    Al-Mendalawi MD; Abdul-Wahab A; Janahi IA; Abdel-Rahman MO
    Saudi Med J; 2010 Mar; 31(3):339-40; author reply 340. PubMed ID: 20231949
    [No Abstract]   [Full Text] [Related]  

  • 24. Exploring cystic fibrosis using bioinformatics tools: a module designed for the freshman biology course.
    Zhang X
    Biochem Mol Biol Educ; 2011; 39(1):17-20. PubMed ID: 21433248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Introduction: molecular chaperones of the ER: their role in protein folding and genetic disease.
    Brooks DA
    Semin Cell Dev Biol; 1999 Oct; 10(5):441-2. PubMed ID: 10597626
    [No Abstract]   [Full Text] [Related]  

  • 26. Novel de novo large deletion in cystic fibrosis transmembrane conductance regulator gene results in a severe cystic fibrosis phenotype.
    Norek A; Stremska M; Sobczyńska-Tomaszewska A; Wertheim-Tysarowska K; Dmeńska H; Jurek M
    J Pediatr; 2011 Aug; 159(2):343-6.e1. PubMed ID: 21663921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genotype-phenotype correlations in cystic fibrosis.
    Kerem E; Kerem B
    Pediatr Pulmonol; 1996 Dec; 22(6):387-95. PubMed ID: 9016472
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacological approaches to cystic fibrosis.
    Bandiera T; Galietta LJV
    Eur J Med Chem; 2021 Apr; 216():113240. PubMed ID: 33691259
    [No Abstract]   [Full Text] [Related]  

  • 29. Cystic fibrosis foundation opens drug discovery lab.
    Trivedi BP
    Science; 2016 Sep; 353(6305):1194-5. PubMed ID: 27634505
    [No Abstract]   [Full Text] [Related]  

  • 30. Quest for cystic fibrosis pharmacotherapy.
    Joo NS
    Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):861-2. PubMed ID: 18714439
    [No Abstract]   [Full Text] [Related]  

  • 31. Nonstop treatment of cystic fibrosis.
    Dietz HC; Hamosh A
    Nat Med; 1996 Jun; 2(6):608-9. PubMed ID: 8640540
    [No Abstract]   [Full Text] [Related]  

  • 32. Gentamicin in pharmacogenetic approach to treatment of cystic fibrosis.
    Hamilton JW
    Lancet; 2001 Dec; 358(9298):2014-6. PubMed ID: 11755605
    [No Abstract]   [Full Text] [Related]  

  • 33. New pharmaceutical approaches to the treatment of cystic fibrosis.
    Delaney SJ; Wainwright BJ
    Nat Med; 1996 Apr; 2(4):392-3. PubMed ID: 8597941
    [No Abstract]   [Full Text] [Related]  

  • 34. [Trends in the treatment of cystic fibrosis].
    Rossi G
    Recenti Prog Med; 1999; 90(7-8):380-2. PubMed ID: 10429516
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapy through chaperones: sense or antisense? Cystic fibrosis as a model disease.
    Amaral MD
    J Inherit Metab Dis; 2006; 29(2-3):477-87. PubMed ID: 16763920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting nonsense-mediated cystic fibrosis: is it premature to stop now?
    O'Sullivan BP
    Lancet Respir Med; 2014 Jul; 2(7):509-11. PubMed ID: 24836206
    [No Abstract]   [Full Text] [Related]  

  • 37. Ignoring the nonsense: a phase II trial in cystic fibrosis.
    Hyde SC; Gill DR
    Lancet; 2008 Aug; 372(9640):691-2. PubMed ID: 18722009
    [No Abstract]   [Full Text] [Related]  

  • 38. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
    Aslam A; Jahnke N; Remmington T; Southern KW
    Paediatr Respir Rev; 2017 Sep; 24():32-34. PubMed ID: 28566196
    [No Abstract]   [Full Text] [Related]  

  • 39. A breath of fresh air.
    Rowe SM; Clancy JP; Sorscher EJ
    Sci Am; 2011 Aug; 305(2):68-73. PubMed ID: 21827128
    [No Abstract]   [Full Text] [Related]  

  • 40. Antagonists to the rescue.
    Welch WJ; Howard M
    J Clin Invest; 2000 Apr; 105(7):853-4. PubMed ID: 10749562
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.